Vonoprazan + Amoxicillin + Clarithromycin + Lansoprazole
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Helicobacter Pylori Infection
Conditions
Helicobacter Pylori Infection
Trial Timeline
Dec 10, 2019 → Mar 18, 2021
NCT ID
NCT04167670About Vonoprazan + Amoxicillin + Clarithromycin + Lansoprazole
Vonoprazan + Amoxicillin + Clarithromycin + Lansoprazole is a phase 3 stage product being developed by Phathom Pharmaceuticals for Helicobacter Pylori Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT04167670. Target conditions include Helicobacter Pylori Infection.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04167670 | Phase 3 | Completed |
Competing Products
6 competing products in Helicobacter Pylori Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy | Sun Pharmaceutical | Approved | 85 |
| Rabeprazole Sodium | Eisai | Pre-clinical | 23 |
| helicobacter pylori vaccine + helicobacter pylori vaccine + helicobacter pylori vaccine + helicobacter pylori vaccine + Placebo + helicobacter pylori vaccine + helicobacter pylori vaccine | Novartis | Phase 1 | 33 |
| H.pylori vaccines + Placebo Vaccine | Novartis | Phase 1 | 33 |
| pantoprazole + bismuth + metronidazole + tetracycline | Pacific Biosciences | Approved | 77 |
| RHB-105 + Active Comparator | RedHill Biopharma | Phase 3 | 69 |